Samsung Biologics has signed a $2.2 billion contract development and manufacturing organization (CDMO) deal with an undisclosed major US pharmaceutical company. The multi-year agreement covers biologics manufacturing at Samsung's Songdo campus, which will have total capacity of 784,000 liters upon completion of Plant 4. This is the largest single CDMO contract in the company's history.
Samsung Biologics' mega-deal confirms South Korea's emergence as the world's premier biologics CDMO hub, rivaling traditional manufacturing centers in the US and Europe.
Samsung Biologics' mega-deal confirms South Korea's emergence as the world's premier biologics CDMO hub, rivaling traditional manufacturing centers in the US and Europe.
$2.2B CDMO contract is Samsung Biologics' largest ever
Manufacturing at Songdo campus with 784,000L total capacity
Reinforces South Korea's position as global biologics manufacturing hub
This mega-deal strengthens South Korea's biopharma leadership within APAC, challenging established players like China's WuXi Biologics and India's Biocon. It signals a regional shift in high-value manufacturing, potentially attracting more foreign direct investment into South Korea's biotech sector. Other APAC nations may seek to emulate this success, fostering increased competition and innovation across the region's CDMO landscape.
Manufacturing at Songdo campus with 784,000L total capacity
Reinforces South Korea's position as global biologics manufacturing hub
Sign in to save notes on signals.
Sign In